|
Charon Robin Ganellin Born Jan 25 1934 Pharmacologically Active Guanidine Compounds Tagamet - Cimetidine Patent Number(s) 3,950,333; 4,024,271 Inducted 1990 Graham J. Durant, John Colin Emmett, and C. Robin Ganellin led the SmithKline Beecham Corporation's research team that discovered the H2 receptor class of drugs, including cimetidine, which inhibits the production of stomach acid. Durant, Emmett, and Ganellin's work, begun in 1964 and done in collaboration with Nobel laureate biologist Sir James Black, established a physiological role for histamine in the control of gastric acid secretions-the major cause of ulcers. Invention Impact The World Health Organization lists cimetidine, known by the brand name Tagamet, as one of the world's most essential drugs for its ability to heal stomach ulcers without surgery. Inventor Bio Ganellin was born in London, England, and studied chemistry at Queen Mary College, London and at the Massachusetts Institute of Technology. He is currently with SmithKline and French professor of medicinal chemistry at University College London, where he is also director of the Upjohn European Discovery Unit. Ganellin is named as co-inventor on more than 100 U.S. patents. |
||||